Abstracts Archive - Page 1044 of 2607 - ACR Meeting Abstracts

Abstract Number: 1558 • 2019 ACR/ARP Annual Meeting
Should Lupus Podocytopathy Be a Subclass in Class I and Class II Lupus Nephritis?
Whitney Bembry¹, Dasha Lopez ², Christopher Mesa ³, Nirupa Patel ³ and Myriam Guevara ⁴, ¹Tulane University School of Medicine, New Orleans, LA, ²Baton Rouge General Hospital, Baton Rouge, LA, ³Louisiana State University School of Medicine, New Orleans, LA, ⁴Louisiana State University School of Medicine, New Orleans
Background/Purpose: Evidence of podocyte effacement on electron microscopy and significant proteinuria in a systemic lupus erythematosus (SLE) patient with biopsy proven minimal mesangial (MM), mesangial…
Abstract Number: 1559 • 2019 ACR/ARP Annual Meeting
Routine Clinical Pathology Measurements Are Predictive of the Risk of Organ Damage Accrual in SLE
Eric Morand¹, Kevin Zhang ¹, Sarah Boyd ¹, Francois Petitjean ¹, Alberta Hoi ², Rachel Koelmeyer ¹ and Hieu Nim ¹, ¹Monash University, Melbourne, Victoria, Australia, ²School of Clinical Sciences, Monash University, Meloburne, Victoria, Australia
Background/Purpose: Prevention of permanent organ damage, a major predictor of morbidity and mortality, is a key goal in the treatment of SLE. Physician-measured disease activity…
Abstract Number: 1560 • 2019 ACR/ARP Annual Meeting
Imbalance Between Th17 and Regulatory T Cells in Patients with Systemic Lupus Erythematosus Combined EBV/CMV Viremia
Rui Su¹, Yue Liu ¹, Xinyu Zheng ¹, Xiao-feng Li ² and Cai-hong Wang ³, ¹Department of Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan , Shanxi, China, Tai Yuan, China (People's Republic), ²Department of Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan , Shanxi, China, TaiYuan, China (People's Republic), ³The Second Hospital of Shanxi Medical University, Tai Yuan, China (People's Republic)
Background/Purpose: Infection is common and is one of the leading causes of morbidity and mortality in Systemic Lupus Erythematosus (SLE) patients . Excessive using glucocorticoid…
Abstract Number: 1561 • 2019 ACR/ARP Annual Meeting
Decreased Nocturnal Blood Pressure Dipping in Patients with Systemic Lupus Erythematosus: Association with Markers of Inflammation
Daniel Carranza Leon¹, Annette Oeser ¹, Qiong Wu ¹, C. Michael Stein ², Michelle Ormseth ¹ and Cecilia Chung ², ¹Vanderbilt University Medical Center, Nashville, ²Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Blood pressure follows a circadian rhythm; usually systolic blood pressure (SBP) drops by more than 10% during the night. Absence of this phenomenon, known…
Abstract Number: 1562 • 2019 ACR/ARP Annual Meeting
The Association of Body Weight Fluctuation and All-Cause Mortality in Patients with Systemic Lupus Erythematosus
Sarah Bayefsky¹, Alyson Dickson ¹, Tyler Reese ¹, Jocelyn Gandelman ², Megan Shuey ¹, April Barnado ¹, Katherine Barker ¹, C. Michael Stein ¹, Vivian Kawai ¹ and Cecilia Chung ¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University School of Medicine, Nashville, TN
Background/Purpose: Recent studies have suggested that body weight fluctuation in the general population is an independent risk factor for overall mortality. These findings are of…
Abstract Number: 1563 • 2019 ACR/ARP Annual Meeting
Interstitial Lung Disease in Patients with Systemic Lupus Erythematosus: Who Should We Screen?
Muhsen Al-ani¹, Bobby Kwanghoon Han ² and Gregory c Gardner ³, ¹University of Washington, seattle, WA, ²University of Washington, seattle, ³University of Wasshington, seattle
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease with a variety of clinical manifestations but interestingly interstitial lung disease (ILD) is rare. The literature to…
Abstract Number: 1564 • 2019 ACR/ARP Annual Meeting
Renal Arteriosclerosis Predicts Cardiovascular Disease in Lupus Nephritis
Shivani Garg¹, Sarah Panzer ², Karen Hansen ³, Callie Plafkin ⁴, Maureen Smith ² and Christie Bartels ¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²UW-Madison, Madison, ³UW Madison, Madison, ⁴UW Health, Madison
Background/Purpose: Patients with lupus nephritis (LN) have a 9-fold higher risk of cardiovascular disease (CVD), highlighting the urgent need to target CVD prevention. Studies in…
Abstract Number: 1565 • 2019 ACR/ARP Annual Meeting
Assessment of the QRISK2, QRISK3, SLE Cardiovascular Risk Equation, Framingham and Modified Framingham Risk Calculators as Predictors of Cardiovascular Disease Events in Systemic Lupus Erythematosus
Jagan Sivakumaran¹, Paula Harvey ², Ahmed Omar ³, Murray Urowitz ³, Dafna Gladman ⁴, Nicole Anderson ³, Jiandong Su ³ and Zahi Touma ³, ¹University of Toronto, Toronto, ON, Canada, ²Women's College Hospital, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is recognized as an independent risk factor for cardiovascular disease (CVD). This study aimed to determine which cardiovascular risk assessment…
Abstract Number: 1566 • 2019 ACR/ARP Annual Meeting
HER2 as a Biomarker of Proliferative Lupus Nephritis in Children
Kathleen Sullivan¹, Jonathan Burnham ², Kathleen O'Neil ³, Laura Schanberg ⁴, Emily von Scheven ⁵, Marisa Klein-Gitelman ⁶ and Patricia Costa Reis ⁷, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²The Children's Hospital of Philadelphia, Philadelphia, PA, ³Indiana University, Indianapolis, IN, ⁴Duke University Medical Center, Durham, NC, ⁵UCSF, San Francisco, CA, ⁶Lurie Children's Hospital, Chicago, IL, ⁷Hospital de Santa Maria, Lisbon, Portugal
Background/Purpose: Lupus nephritis is a common feature of SLE and confers a poor prognosis. 20-50% of patients with lupus nephritis ultimately develop chronic kidney disease…
Abstract Number: 1567 • 2019 ACR/ARP Annual Meeting
Cachexia in Systemic Lupus Erythematosus
George Stojan¹, Jessica Li ² and Michelle Petri ², ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Cachexia is a syndrome that may accompany a range of diseases, including cancer, chronic heart failure, chronic obstructive pulmonary disease, and rheumatoid arthritis. It…
Abstract Number: 1568 • 2019 ACR/ARP Annual Meeting
High Risk Low Attenuation Non-Calcified Coronary Plaque in Lupus vs. Controls
George Stojan¹, Jessica Li ² and Michelle Petri ², ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The presence of low attenuation noncalcified plaque (< 30 Haunsfield units) is one of the most characteristic vessel changes in unstable coronary plaques. Low-attenuation…
Abstract Number: 1569 • 2019 ACR/ARP Annual Meeting
Poor Long-term Renal Outcome in Systemic Lupus Erythematosus Without Abnormal Urinalysis: A Possible Link with Silent Lupus Nephritis
Hironari Hanaoka¹, Jun Kikuchi ², Shuntaro Saito ¹, Hiroshi Takei ³, Kazuoto Hiramoto ¹, Tatsuhiro Oshige ¹, Noriyasu Seki ⁴, Hideto Tsujimoto ⁴, Yuko Kaneko ¹ and Tsutomu Takeuchi ⁵, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Keio Universitiy School of Medicine, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, ⁴Mitsubishi Tanabe Pharma Corporation Sohyaku, Tokyo, ⁵Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Background/Purpose: It has been well investigated that patients with lupus nephritis (LN) have worse prognosis than those without. Recently reported, about 20% of SLE…
Abstract Number: 1570 • 2019 ACR/ARP Annual Meeting
Can the Montreal Cognitive Assessment (MoCA) Improve the Automated Neuropsychological Assessment Metrics (ANAM) Performance in Screening for Cognitive Impairment in Lupus Patients?
Oshrat Tayer-Shifman¹, Robin Green ², Dorcas Beaton ³, Lesley Ruttan ², Joan Wither ⁴, Maria Tartaglia ⁵, Mahta Kakvan ¹, Sabrina Lombardi ², Nicole Anderson ¹, Jiandong Su ¹, Dennisse Bonilla ¹, Moe Zandy ¹, May Choi ⁶, Marvin Fritzler ⁶ and Zahi Touma ⁷, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³St. Michael's Hospital, Toronto, ON, Canada, ⁴University Health Network, Krembil Research Institute, Toronto, ON, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷University Health Network, University of Toronto, Toronto, Canada
Background/Purpose: : In a related study, we have shown evidence to support the validity of the Automated Neuropsychological Assessment Metrics (ANAM) for the screening of…
Abstract Number: 1571 • 2019 ACR/ARP Annual Meeting
Validity Evidence Supports the Use of Automated Neuropsychological Assessment Metrics (ANAM) as a Screening Tool for Cognitive Impairment in Patients with Systemic Lupus Erythematosus
Oshrat Tayer-Shifman¹, Robin Green ², Dorcas Beaton ³, Lesley Ruttan ², Joan Wither ⁴, Maria Tartaglia ⁵, Mahta Kakvan ¹, Sabrina Lombardi ², Nicole Anderson ¹, Jiandong Su ¹, Dennisse Bonilla ¹, Moe Zandy ¹, May Choi ⁶, Marvin Fritzler ⁶ and Zahi Touma ⁷, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³St. Michael's Hospital, Toronto, ON, Canada, ⁴University Health Network, Krembil Research Institute, Toronto, ON, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷University Health Network, University of Toronto, Toronto, Canada
Background/Purpose: Cognitive impairment (CI) is highly prevalent in Systemic Lupus Erythematosus (SLE). Screening for CI in SLE may be delayed, if relying on the American…
Abstract Number: 1572 • 2019 ACR/ARP Annual Meeting
Persistent Cognitive Impairment in Lupus Patients over 1 Year and Associated Factors
Dorcas Beaton ¹, Robin Green ², Lesley Ruttan ², Joan Wither ³, Oshrat Tayer-shifman⁴, Maria Tartaglia ⁵, Mahta Kakvan ⁴, Nicole Anderson ⁴, Jiandong Su ⁴, Moe Zandy ⁴, May Choi ⁶, Marvin Fritzler ⁶ and Zahi Touma ⁴, ¹St. Michael's Hospital, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³University Health Network, Krembil Research Institute, Toronto, ON, Canada, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Cognitive impairment (CI) is a common manifestation of systemic lupus erythematosus (SLE) and its course may change over time. The objective was to determine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].